Proteon Therapeutics (PRTO) Receiving Somewhat Critical Media Coverage, Report Shows

Business



[ad_1]

Proteon Therapeutics logo "title =" Proteon Therapeutics logo "clbad =" companylogo "/> Headlines about Proteon Therapeutics (NASDAQ: PRTO) have been trending somewhat negative this week, Accern Sentiment reports. coverage by monitoring more than 20 million blogs and news sources in real time. Accor's Scale Accumulated Impact on the Biopharmaceutical Company's Impact Score of 46.0258193469341 Out of 100, Several Recent Dealings Have Come Unstuck (19659002) reports on PRTO Brookline Cap M reaffirmed a "buy" rating on shares of Proteon Therapeutics in a report on Tuesday, June 26th. of Proteon Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, June 2nd. Cowen reaffirmed a "hold" rating on shares of Proteon Therapeutics in a report on Thursday, May 10th. HC Wainwright raised shares of Proteon Therapeutics from a "neutral" rating to a "buy" rating of $ 3.00 target price for a report on Thursday, May 10th. Finally, Robert W. Baird reaffirmed an "outperform" rating on shares of Proteon Therapeutics in a report on Thursday, March 15th. Four research badysts have rated the stock market with a hold rating. The company currently has a consensus rating of "Hold" and an average target price of $ 2.83. </p> <p> Proteon Therapeutics stock traded down $ 0.15 during trading hours on Friday, hitting $ 2.65. The stock had a trading volume of 20,248 shares, compared to its average volume of 38,075. The stock has a market capitalization of $ 46.84 million, a PE ratio of -1.24 and a beta of 1.51. Proteon Therapeutics has a 12-month low of $ 1.25 and a 12-month high of $ 2.90. </p> <p> Proteon Therapeutics (NASDAQ: PRTO) last Wednesday, May 9th. The biopharmaceutical company reported ($ 0.34) EPS for the quarter, topping badysts' consensus estimates of ($ 0.37) by $ 0.03. Proteon Therapeutics will post -1.34 earnings per share for the current fiscal year. </p> <p> <strong> Proteon Therapeutics Company Profile </strong> </p> <p> Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. <!--ViewCount:ArticleHistoryID=21153436&PostDate=2018-7-8&type=m&id=476141--></p> <p style= Receive News & Reviews for Proteon Therapeutics Daily </strong> – Product Monograph for Prodeon Therapeutics (19659007) Enter your email address to get a concise daily summary of the latest news and badysts' ratings for Proteon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter. </p> <p><!-- End Footer Opt-In --></p></div> </pre> [ad_2] <br /><a href=Source link

Tags

Powered by https://naaju.com/ireland | Designed by Naaju
© Copyright 2024, All Rights Reserved